Bavarian Nordic A/S Earnings Recaps
Q2 2025
Aug 22, 2025
Bavarian Nordic reported a robust 33% revenue increase in the first half of 2025, driven by strong vaccine sales and a significant EBITDA margin expansion to 32%.
Key takeaways
- Achieved DKK 3.1 billion in Public Preparedness contracts, exceeding previous forecasts.
- Sales of rabies and TBE vaccines fueled a 24% growth in Travel Health division.
- Priority Review Voucher sale resulted in net income of DKK 810 million, boosting year-end EBITDA margin projection to 42%.
- Successfully launched the Chikungunya vaccine in multiple regions, with further expansion plans in place.
- Company maintains a balanced growth strategy and refines revenue guidance while targeting an EBITDA margin of 26-30%.